Personally, I am quite content that the assays have been delayed. As long as the assays are in the lab, the market will continue to support a speculative premium in the BMK share price - the blue sky effect. With the BMK assays due in 2-3 weeks, there is a strong liklihood for NOT to release core visual information first.

If NOT hits, I believe the runup for BMK will be higher with assays still in the lab, than if they've been released. Why? The current speculative premium seems to be based on BMK achieving NOT-like results, and there is a (likely IMO) possibility that although BMK assays may 'be good', that they will not be what the market expects this time and focus will shift to when their drills start turning again.

If an area play hits while BMK assays are in lab, I think the timing may present a significant opportunity.